Should You Invest In These Medical Companies? Geron Corporation(NASDAQ:GERN), Hemp Inc(OTCMKTS:HEMP), and Navidea Biopharmaceuticals Inc(NYSEMKT:NAVB)

Posted by admin August 5, 2014 0 Comment 2631 views

New York, NY – 08/5/2014 –  HotStockGains provides investors  and traders with valuable trading strategies via text message and email. To join our free text message alerts service just text the word BREAKOUT to 555888 from your cell phone. Just text STOP to unsubscribe if you ever need to.

Geron Corporation(NASDAQ:GERN) gained fourteen cents during yesterday’s trading, a 6.01% increase in value that moved the stock to a closing price value of $2.47. The stock has traded within a range of $1.20 to $7.36 over the past 52 weeks, indicating that yesterday’s closing price is still a disappointing mark for California-based clinical stage biopharmaceutical company. Geron Corporation will be holding a conference call to discuss its second quarter results on August 11th, 2014. The stock’s value has not changed in after-hours trading.

Should You Invest In Geron Corporation Before The Company Announces Its Second Quarter Results? View Our Free GERN Analysis.

Hemp Inc(OTCMKTS:HEMP) suffered a 2.31% decrease in value during yesterday’s trading, losing $0.0013 to close at $0.0549. This new mark moves the stock even further away from its 52 week low of $0.34. On Friday, the Las Vegas-based medical marijuana services and products company, which employs a total of four individuals full-time, applauded the U.S. House of Representatives for their efforts to pass bipartisan medical marijuana legislation. Hemp, Inc. also cited the efforts of U.S. Senator Rand Paul, who has proposed a bill to protect the rights of states that have legalized medical marijuana.

What Would New Legislation Mean For Hemp? Take A Look At Our Free HEMP Analysis.

Navidea Biopharmaceuticals Inc(NYSEMKT:NAVB) fell seven cents during yesterday’s trading, a 5.38% loss in value that moved the stock to a closing price of $1.23. The new mark places the clinical-stage biopharmaceutical company just twelve cents above its 52 week low of $1.11. On July 16th, the Ohio-based company announced it had entered into an agreement with Rheumco, LLC to develop “radiolabeled diagnostics and therapeutics for rheumatologic and arthritic diseases.” Navidea will be announcing its second quarter financial results on August 6th, 2014.

Can Navidea Corporation Remain Above The $1 Mark? Click Here For A Free NAVB Analysis.

About HotStockGains

I have a confession to make – I am not always right. Sometimes, unfortunately, I will send alerts that experience losses.

I have alerted companies that rallied 100% or even 6,000% (not even joking) in under a week. Likewise, I have alerted companies that tanked 10, 20, sometimes even as much as 30 or 40%. However overall it is about the net result that delivers profits into your portfolio.

Sign up for my free newsletter to receive market insight, tips, and trading strategies on NYSE, NASDAQ, OTCBB and PINK stocks. If you are not satisfied, simply click unsubscribe.

Disclosure:  HotStockGains is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor (I am not one). Please visit for complete risks and disclosures.

Write Your Comment